Crypto News: Just Hit the Radar: See Why (QNTM) Will Be Topping Our Screens Tomorrow AM

Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Quantum BioPharma Ltd.

Daily Edge Report Just Put (QNTM) On Tomorrow Morning's Early Watchlist —Wednesday, April 1, 2026.

Don't miss the next breakout — get real-time alerts sent straight to your phone!

Expect Full Coverage On (QNTM) To Start Early

Pull Up (QNTM) Before Tomorrow Morning…

March 31, 2026

Just Hit the Radar: See Why (QNTM) Will Be Topping Our Screens Tomorrow AM

Dear Reader,

As biotech races toward faster, smarter dr-ug development, one major advantage is starting to separate certain companies from the rest: the ability to pair breakthrough science with advanced computational power.

In today's market, the companies attracting attention are not just the ones developing treatments, they're the ones building more efficient ways to identify, evaluate, and advance them.

That trend is becoming increasingly important in areas like neurodegenerative disease and metabolic disorders, where the need for better solutions remains massive and the margin for error in development is high.

As a result, biotech names operating at the crossroads of specialized therapeutics and data-driven discovery are beginning to stand out for their broader upside potential and strategic flexibility.

The company is leveraging advanced computing alongside targeted medical research as it works to develop novel candidates in high-need therapeutic categories.

And that's exactly why (QNTM) is landing at the top of our watchlist heading into tomorrow morning — Wednesday, April 1, 2026.

One more thing worth noting: (QNTM) has fewer than 4M shares listed as available to the public. When a company carries a float this small, it can create the setup for sharp movement if interest starts building.

Analyst Targets Point to 700% to 1,000%+ Upside Potential From Recent Levels

Analyst coverage on (QNTM) has already started to reflect the scale of the opportunity some see developing here.

At recent levels near $4, published targets imply substantial upside potential from current trading levels.

Singular Research has placed a $35.50 target on (QNTM), which suggests more than 700% upside potential.

Meanwhile, Kingswood Capital Partners has issued a $45 target, implying over 1,000% upside potential from the company's recent range.

That outlook comes as the company continues to sharpen its identity and long-term positioning.

Formerly known as Lucid BioPharma, the company rebranded to better reflect its broader strategic focus.

With a pipeline targeting both neurodegenerative diseases and metabolic disorders, (QNTM) is working to build a more modern biotech model — one that combines traditional therapeutic development with a technology-driven discovery approach.

And the deeper you dig into the company's clinical programs, strategic direction, and computational angle, the easier it becomes to understand why (QNTM) has started attracting more attention.

What's Emerging Behind Quantum BioPharma (NASDAQ: QNTM)

Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focused on developing innovative therapeutic candidates for areas of significant unmet medical need.

The company's pipeline is centered around programs targeting neurodegenerative diseases and metabolic disorders, two large and complex healthcare markets where demand for new treatment approaches remains substantial.

What helps differentiate (QNTM) is its effort to combine specialized biomedical research with advanced computational analysis, creating a more modern framework for therapeutic discovery and development.

Formerly known as Lucid BioPharma, the company rebranded to Quantum BioPharma to better reflect its broader strategic direction and evolving focus at the intersection of life sciences and technology-enabled innovation.

As biotech continues shifting toward more efficient, data-driven development models, (QNTM) is positioning itself within a segment of the market that could become increasingly relevant in the years ahead.

See Company Presentation

A Pipeline Built Around High-Need Neurology and Specialty Therapeutics

At the center of the (QNTM) story is a pipeline that targets areas with major unmet medical need, led by its multiple sclerosis program and supported by additional therapeutic and commercial-stage assets.

Lucid-MS (Lucid-21-302) | Multiple Sclerosis

(QNTM)'s lead asset, Lucid-MS, is being developed as a first-in-class oral candidate for multiple sclerosis with a differentiated mechanism focused on preventing demyelination and supporting myelin protection — a different angle than many currently available MS therapies. According to the company, Phase 1 dosing in healthy volunteers has been completed, and the program has continued advancing through key development steps.

More recently, (QNTM) announced completion of dosing in both 180-day repeated-dose toxicity and toxicokinetic studies for Lucid-MS. Those studies are expected to support the company's planned IND submission to the FDA and help inform the design of a future Phase 2 trial in patients with multiple sclerosis.

(QNTM) has also been laying the groundwork operationally. In 2024, (QNTM) announced an agreement to conduct an observational study in patients with primary progressive multiple sclerosis, which the company said is intended to help support future Phase 2 planning. In 2025, it also signed a manufacturing agreement with a CDMO to produce the oral formulation planned for that next stage of development.

Unbuzzd™ | Alcohol Misuse / Consumer Health

Outside of Lucid-MS, (QNTM) also has exposure to the alcohol misuse / wellness category through unbuzzd™, a product positioned around helping reduce blood alcohol levels and support recovery after alcohol consumption. The company has continued highlighting this asset in recent corporate updates, giving it a more diversified profile than a typical single-asset biotech story.

Taken together, the company's pipeline gives (QNTM) exposure to a mix of clinical-stage neurology development and adjacent specialty therapeutic / consumer-health markets.

Strategic Positioning, Partnerships, and Built-In Optionality

A key part of the (QNTM) story is the way the company has worked to strengthen its long-term strategic position through both intellectual property protection and development partnerships.

Quantum BioPharma has secured access to exclusively licensed patent families designed to protect both its neuroprotective compounds and elements of its computational discovery platform, helping support a broader IP moat around its development model.

And on March 30, 2026, the company added another notable step forward when it signed a binding Letter of Intent with Allucent, a global contract research organization, to support the planned Phase 2 clinical trial for Lucid-MS.

Beyond its core pipeline, (QNTM) also maintains additional financial upside through assets it has already spun out.

The company currently holds a 19.84% ownership stake in Unbuzzd Wellness Inc., while also retaining the right to receive 7% royalties on sales up to $250M, followed by a 3% royalty in perpetuity thereafter.

On top of that, Quantum BioPharma also retains an estimated C$130M in tax loss carryforwards, which could provide meaningful future value by helping offset taxes against potential future profits.

Taken together, these layers of IP protection, clinical development support, equity exposure, royalty participation, and tax assets help give (QNTM) a more flexible and strategically layered profile than many early-stage biotech names.

Recent Milestones Moving Lucid-MS Forward

Over the past several months, (QNTM) has continued advancing its lead multiple sclerosis program, Lucid-MS, through a series of important development milestones.

Phase 2 Trial Timeline Taking Shape: On March 30, 2026, Quantum indicated it is targeting Q2 2026 to initiate its Phase 2 trial for Lucid-MS, following its strategic collaboration with Allucent.

Clinical Validation for Unbuzzd™: On March 23, 2026, results from a clinical study on unbuzzd™ were published in a peer-reviewed journal, highlighting measurable improvements in BAC reduction and symptom recovery.

Year-End Financial Position Confirmed: (QNTM) reported its 2025 audited financials, confirming a solid balance sheet and no "going concern" qualification.

Phase 2 Leadership Put in Place: (QNTM) appointed a Principal Investigator for its upcoming multiple sclerosis study, further advancing its clinical execution framework.

Safety Package Completed: The company also finalized 180-day repeated-dose oral toxicity studies for Lucid-MS, reporting no significant toxicity or adverse effects, a key step supporting progression into human efficacy trials.

Where Financial Strength Meets Market Potential

(QNTM) reported approximately $11.3M in ca-sh and digital assets, which management believes is sufficient to support core operations into early 2028, providing close to two years of runway.

The company has also made progress strengthening its balance sheet, reducing trade payables by roughly 50% year-over-year, from $4.1M down to $2.0M.

From a market standpoint, Quantum is operating across large and expanding sectors, including the multiple sclerosis market projected to reach ~$38B by 2030 and the broader mental health market estimated at ~$238B.

With a current market capitalization near $22M, the company sits at a stage where upcoming Phase 2 clinical progress could begin to play a larger role in shaping how the market values its pipeline.

7 Factors Putting (QNTM) At The Top Of Our Watchlist Tomorrow Morning—Wednesday, April 1, 2026

1. Small Float: With fewer than 4M shares available to the public, (QNTM) has the kind of structure that can react quickly if attention starts building.

2. Big Analyst Targets: Published targets of $35.50 and $45 imply roughly 700% to 1,000%+ upside potential from its recent $4 range.

3. Phase 2 Setup: A binding LOI with Allucent and an expected Q2 2026 Phase 2 launch put a clear near-term milestone on the table.

4. Oral MS Candidate: Its lead program, Lucid-MS, is being developed as an oral multiple sclerosis candidate, giving it a differentiated angle in the space.

5. Published Validation: Peer-reviewed data tied to unbuzzd™ showed BAC reduction more than 40% faster than placebo in the first 30 minutes.

6. Capital Runway: As of March 27, 2026, the company reported $11.3M in ca-sh and digital assets, with runway projected into 2028.

7. Extra Embedded Value: A 19.84% stake in Unbuzzd Wellness, ongoing royalty rights, and roughly C$130M in tax loss carryforwards add additional layers to the story.

Pull Up (QNTM) Before The Morning…

When you put the full picture together, (QNTM) starts to stand out as more than just another early-stage biotech name.

Between its low float structure, analyst targets, upcoming Phase 2 milestone, and a pipeline centered around high-need therapeutic markets, the company has several factors that could keep it on the radar in the near term.

Add in its capital position, strategic optionality, and exposure to additional value drivers beyond its lead program, and it becomes easier to understand why (QNTM) has started drawing fresh attention.

That's exactly why (QNTM) is landing near the top of our watchlist heading into Wednesday Morning, April 1, 2026.

(QNTM) will be front and center as we head into tomorrow.

Pull up (QNTM) before calling it a night.

Sincerely,

Joel Locke
Senior Editor
The Daily Edge Report

_{DailyEdgeReport.com}_{("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA)}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 03/31/2026 and ending on 04/01/2026 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC fifteen thousand USD ("Funds"). To date, including under the previously described agreement, GG Media Holdings LLC has been paid twenty one thousand five hundred USD ("Funds"). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA).}

_{Please see important disclosure information here:}_{https://dailyedgereport.com/disclosure/qntm-kIb3k/#details}